Lung Yi Mak

BACKGROUND: While sodium-glucose cotransporter 2 inhibitors improves cardiovascular and renal outcomes irrespective of diabetes mellitus (DM) status, their effects in metabolic-dysfunction associated steatotic liver disease (MASLD) patients without diabetes mellitus (DM) are unknown…